This inventor holds 2 USPTO granted patents. Top assignee: Lupin Laboratories Limited. Active years: 1998.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Madhya Pradesh, IN (1998)
- Mandideep, IN (1998)
Company Filing History:
Years Active: 1998
Title: Innovations by Tumma Hari Krishna
Introduction
Tumma Hari Krishna is a notable inventor based in Madhya Pradesh, India. He has made significant contributions to the field of pharmaceuticals, particularly in the synthesis of compounds used in antibiotic production. With a total of 2 patents to his name, his work is recognized for its impact on medical advancements.
Latest Patents
His latest patents include a process for the stereospecific synthesis of a keto-enol tautomeric mixture of p-nitrobenzyl (1R,6R,7R)-7-phenoxyacetamido-3-oxo-3-cepham-4-(R/S)-carboxylate-1-oxide and p-nitrobenzyl (1R,6R,7R)-7-phenoxyacetamido-3-hydroxy-3-cephem-4-carboxylate-1-oxide. These compounds serve as valuable intermediates for the synthesis of cephalosporin antibiotics, such as cefaclor. The detailed processes he has developed are crucial for enhancing the efficiency of antibiotic production.
Career Highlights
Tumma Hari Krishna is associated with Lupin Laboratories Limited, a prominent player in the pharmaceutical industry. His work at this company has allowed him to focus on innovative solutions that address critical health challenges. His expertise in chemical synthesis has positioned him as a key contributor to the development of new pharmaceutical products.
Collaborations
He has collaborated with notable colleagues, including Ramanathan Sankaran and Sugata Chattejee. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Tumma Hari Krishna's contributions to pharmaceutical innovation through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to influence the development of essential medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile